Moore Capital Management’s AstraZeneca AZN Stock Holding History

Moore Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-33,150	Closed	-$4.49M	–	448
2023 Q3	$4.49M	Sell	33,150 -91,850	-73%	-$12.5M	0.08%	176
2023 Q2	$17.9M	Buy	+125,000	New	+$18.4M	0.31%	65

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Sanders Capital West Palm Beach, Florida $83.9B AUM 37.89% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Moore Capital Management's AZN Position: Q4 2023 in Review

Moore Capital Management sold out of AstraZeneca (AZN) in Q4 2023, closing a stake of 25,000 shares — an estimated $3.39M sold.

Moore Capital Management first reported a position in AZN in Q2 2014 and held it in 4 quarters. The position peaked at $24M in Q4 2021. 1,131 funds tracked by Wall St. Rank hold AZN as of Q4 2023.

Moore Capital Management reported no remaining AstraZeneca position as of Q4 2023 after selling out during the quarter.
Moore Capital Management sold 25,000 AstraZeneca shares in Q4 2023, an estimated $3.39M.
Moore Capital Management first reported a position in AstraZeneca in Q2 2014 and held it in 4 quarters.
Moore Capital Management's AstraZeneca position peaked at $24M in Q4 2021.
1,131 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2023.

Based on Moore Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.